Lexaria Corp CSE:LXX OTC:LXRP

Lexaria has been awarded one Patent for “Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof” and have filed a dozen others. All related to their unique lipophilic enhancement technology that has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. Cannabinoids are poorly absorbed by the body’s gastrointestinal tract and consumers often default to alternate routes of administration like smoking to achieve higher effectiveness.

Independent Lab results have confirmed that the technology enhances the bioavailability by 5 times and masks taste. This means users can use less and save more and have an alternative to smoking or vaporizing.

Furthermore, through a JV with NeutriSci (TSXV:NU) using their proprietary pterostilbene tablet formula and Lexaria's technology - were combined to produce the first market-ready pterostilbene/cannabidiol rapid-melt edible product.

The pretrial hypothesis focused on whether the combination of NeutriSci's patented pterostilbene formula and Lexaria's patented CBD conjugation would prove effective in rapidity of onset, and strength of effect, while delivering improvements in taste. These initial trial results have demonstrated that the consumer experiences positive effects that occur more immediately, and last longer, while utilizing dose-controlled amounts of CBD.

Currently, Lexaria has six closed or pending sales/royalty agreements so revenues will start to build. They have been awarded one Patent for “Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof” and there is 12 other applications filed.

www.lexariaenergy.com